Abstract
Antibodies against human leukocyte antigens (HLA) are closely related to engraftment, hematopoietic reconstitution, graft-versus-host disease, and are crucial for guiding treatment strategies and prognostic assessment in allogeneic hematopoietic stem cell transplantation (allo-HSCT) . The anti-HLA antibody detection and result analysis are not only affected by the inherent limitations and sensitivity of the testing methods, but also depend on the performance validation of key procedures, comprehensive quality, and standardized data analysis, which demand higher standards for result interpretation and reporting. To address these issues, the Experimental Diagnostics Group, Chinese Society of Hematology, Chinese Medical Association has developed this expert consensus, aiming to make the anti-HLA antibody detection play a more important role in the clinical diagnosis and treatment of allo-HSCT.